EP3366283

NOVARTIS AG
Application Number
EP18165545A
Filing Date
Jan 17, 2005
Status
Granted And Under Opposition
Jul 30, 2021
Grant Date
Sep 1, 2021
External Links
Slate, Register

Biblio Summary

The patent EP3366283B1 was granted on Sep 1, 2021 by Novartis Ag The patent is currently Granted And Under Opposition.

The table below shows 6 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

HOFFMANN EITLEJun 1, 2022WITHDRAWN
HAMM&WITTKOPP PATENTANWALTE PARTMBBMay 30, 2022WITHDRAWN
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBMay 30, 2022WITHDRAWN
INSTONE TERRY/ READ HOWARD GRAHAM/APPLEYARD LEES IP LLPMay 23, 2022WITHDRAWN
D YOUNG & CO LLPMay 19, 2022WITHDRAWN
COOKE, RICHARDSep 28, 2021WITHDRAWN

The table below shows the patents of Novartis Ag that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3124018Oral Formulations Of DeferasiroxApr 24, 20242
EP4159204Novel Pharmaceutical CompositionFeb 14, 20244
EP4159205Novel Pharmaceutical CompositionFeb 14, 20245